Slovenien - slovensk - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

jenson - klopidogrel - filmsko obložena tableta - klopidogrel 75 mg / 1 tableta - klopidogrel

Slovenien - slovensk - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pentafarma - sociedade technico-medicinal, s.a. - klopidogrel - filmsko obložena tableta - klopidogrel 75 mg / 1 tableta - klopidogrel

Slovenien - slovensk - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

filmsko obložena tableta - klopidogrel

Slovenien - slovensk - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

norgine bv - klopidogrel - filmsko obložena tableta - klopidogrel 75 mg / 1 tableta - klopidogrel

Slovenien - slovensk - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

filmsko obložena tableta - klopidogrel

Den Europæiske Union - slovensk - EMA (European Medicines Agency)

the medicines company uk ltd - bivalirudin - akutni koronarni sindrom - antitrombotična sredstva - angiox je indiciran kot antikoagulant pri odraslih bolnikih s perkutano koronarnim posegom (pci), vključno z bolniki z miokardnim infarktom elevacije st (stemi), ki se podvrže primarni pci. angiox je prikazano tudi za zdravljenje odraslih bolnikov z nestabilno angino pektoris / non-st-segmenta,-dvig miokardni infarkt (ua / nstemi) načrtovana za nujne ali zgodnje intervencije. angiox je treba dajati z aspirinom in clopidogrel.

Den Europæiske Union - slovensk - EMA (European Medicines Agency)

bayer ag - rivaroksaban - arthroplasty, replacement; venous thromboembolism - antitrombotična sredstva - xarelto, co-daje z acetilsalicilne kisline (asa) samostojno ali s asa plus clopidogrel ali ticlopidine, je označen za preprečevanje atherothrombotic dogodkov pri odraslih bolnikih po akutni koronarni sindrom (acs) s povišano srčno biomarkerje. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. preprečevanje venska trombembolija (vte) pri odraslih bolnikih, ki so v postopku izbirni kirurški zamenjavi kolka ali kolena. zdravljenje globoke venske tromboze (dvt) in pljučna embolija (pe), in preprečevanje ponavljajočih se dvt in pe pri odraslih. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Den Europæiske Union - slovensk - EMA (European Medicines Agency)

merck sharp dohme limited - vorapaxar sulfat - miokardni infarkt - antitrombotična sredstva - zontivityis so navedeni za zmanjšanje atherothrombotic dogodkov pri odraslih bolnikih z - zgodovina miokardni infarkt (mi)co-daje z acetilsalicilne kisline (asa) in, kjer je primerno, clopidogrel; ali - simptomatsko periferne arterijske bolezni(pad), co-daje z acetilsalicilne kisline (asa) ali, kjer je primerno, clopidogrel.

Den Europæiske Union - slovensk - EMA (European Medicines Agency)

mylan ireland limited - rivaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotična sredstva - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.